HOME >> MEDICINE >> NEWS
Takeda responds to the FDA advisory committee recommendation

Deerfield, IL, July 30, 2007 Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS ; (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

The breadth and depth of ACTOS data encompassing more than 16,000 patients over the past 10 yearsis consistent: Short- and long-term studies, both prospective and observational, studies in both humans and animals, all have shown no evidence that ACTOS is associated with an increased risk of heart attack or stroke, said Mehmood Khan, M.D., TGRD president. Critical in this body of data is the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study, since the only scientific way to determine a medications safety is a prospective, long-term trial.

About the PROactive Study

PROactive was a prospective, randomized, placebo-controlled outcomes trial. The PROactive study included 5,238 patients with type 2 diabetes and a history of macrovascular disease, who were force titrated up to 45 mg daily of either ACTOS or placebo. In this study, there was no difference in the number of macrovascular events between standard of care and ACTOS, and standard of care alone. Although there was no statistically significant difference between ACTOS and standard of care for the primary endpoint, there was no increase in mortality or total macrovascular events with ACTOS.

The ACTOS Prescribing Information was recently revised by the FDA to include this reassuring cardiovascular safety data. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Although drugs may be in the same class, they also can have different clinical effects due to differences
'"/>

Contact: Cristina Sotolongo
Cristina.Sotolongo@ketchum.com
646-935-4021
Ketchum
30-Jul-2007


Page: 1 2

Related medicine news :

1. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Stubborn ulcerative colitis responds to arthritis drug, review finds
4. American Egg Board responds to proposed USDA rule to revise WIC food package
5. Bradley Hospital responds to FDA report on ADHD drugs
6. Life-threatening lupus responds to stem cell transplant therapy
7. Pain research using electronic diaries helps identify who responds to placebo effect
8. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
9. ARRS president responds to NAS report on ionizing radiation
10. Medical, IT, engineering experts form advisory panel for electronic health record safety
11. National Academies advisory: Native African vegetables

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... , ... Just found out your dear friend has cancer? , It’s hard to hear your ... shares their diagnosis. Once the shock wears off, the questions and fears can be overwhelming. ... best ways to help? Words are failing me. I’m scared. I want to DO something. ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University Global (CSU ... affordable online education – is proud to announce its new master’s degree in ... its kind in the nation, the 60-credit hour program is designed to provide ...
(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give back to ... 10 percent of each hotel room booked with a special new rate code to ... Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any room type, ...
(Date:8/28/2020)... ... 28, 2020 , ... Ernst & Young LLP (EY US) ... Of The Year® 2020 Florida Award finalist. Now in its 34th year, the ... growth and prosperity as they build and sustain successful businesses that transform our ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... Integrated ... Miami is the first Florida school to deploy its breakthrough Mobile Biodefense Indoor Air ... airborne COVID-19. True North Classical Academy plans to fully reopen equipped with the filtration ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... While coronavirus cases continue to increase across ... and community organizations remain closed. Because about 80% of blood donations are made at ... blood donors and blood drive hosts to ensure blood products are readily available for ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... If you live in New York City ... real estate part makes sense, it’s the law of supply and demand, but are plastic ... has a significant percentage of their patients that make the four-hour trip to have ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... Dr. ... reproductive and endoscopic surgeon and serves as a clinical professor in the Department of ... of the American Laparoscopy Society & Pacific Coast Reproductive Society and is a Clinical ...
Breaking Medicine Technology:
Cached News: